Skip to main content

$0.750 0.045 (6.38%)

High

$0.75

Low

$0.72

Trades

192

Turnover

$235,210

Volume

320,189
30 June 2023 at 4:10pm
Register to track VHT and receive email alerts.
Subject
VHT Ann: Volpara Quarterly Results and Investor Webinar Notification

VHT Ann: Supplemental disclosure in relation to contract win

VHT Ann: Volpara Q2FY22 Business Update and Morgans Presentation

VHT Ann: Volpara signs largest deal to date with US imaging leader

VHT Ann: Volpara to collaborate with genetics leader Natera

VHT Ann: Notification of cessation of securities - VHT

VHT Ann: Volpara Positioning for Growth in Lung Cancer Screening

VHT Ann: Change in substantial holding

VHT Ann: US lung cancer screening expansion investor webinar

VHT Ann: Volpara to Invest in RevealDX Lung Cancer AI

VHT Ann: Volpara Small and Mid-Cap conference Presentation

VHT Ann: Volpara and Riverain to Partner on Lung Cancer AI

VHT Ann: Initial Director's Interest Notice - A Custin

VHT Ann: Application for quotation of securities - VHT

VHT Ann: Volpara confirms Board changes to drive US growth

VHT Ann: Change of Director's Interest Notice - R Allen

VHT Ann: Notification regarding unquoted securities - VHT

VHT Ann: Final Director's Interest Notice - M Saini

VHT Ann: Results of Meeting

VHT Ann: AGM Presentation 2021

VHT Ann: FDA clears Volpara's next generation imaging software

VHT Ann: Appendix 4C Q1FY22 Quarterly Cash Flow Report

VHT Ann: Annual General Meeting Letter to Shareholders

VHT Ann: Notice of Annual General Meeting/Proxy Form

VHT Ann: VOLPARA COLLABORATES WITH LEADING GENETICS COMPANY, INVITAE

VHT Ann: Volpara Quarterly Results and Investor Webinar Notification

VHT Ann: Volpara extends IP portfolio with new European patent

VHT Ann: Notification regarding unquoted securities - VHT

VHT Ann: Notification of cessation of securities - VHT

VHT Ann: Volpara to present at UBS-hosted Investor Demonstration Day

VHT Ann: Change of Director's Interest Notice - M Saini

VHT Ann: Change of Director's Interest Notice - M Saini

VHT Ann: Appendix 2A

VHT Ann: FY21 Full Year Results Presentation

VHT Ann: FY21 Annual Report to Shareholders

VHT Ann: Appendix 4G - Corporate Governance Statement

VHT Ann: Preliminary Final Report

VHT Ann: Volpara to present at the Share Cafe Hidden Gems Webinar

VHT Ann: Notice of Annual Results and Investor Conference Call

VHT Ann: Volpara May Newsletter

VHT Ann: Appendix 4C - quarterly

VHT Ann: Volpara Quarterly Results and Investor Webcast Notification

VHT Ann: Volpara Q4FY21 Business Update

VHT Ann: US patent protects key features of Volpara clinical software

VHT Ann: DENSE trial using Volpara shows excellent 2nd-round results

VHT Ann: Volpara Signs Highest Value Contract to Date via CRA Health

VHT Ann: Investor Presentation to Craigs Investment Partners

VHT Ann: Appendix 2A

VHT Ann: Appendix 3G

VHT Ann: CRA Health Acquisition Presentation

Register to track VHT and receive email alerts.

Similar Companies

ADR